Raul Delapena Setiawan
Ammar Sabilarrohman
Lina Irawan
Suro Senen
Pevita Pearce
In a landmark development for neurotechnology, Science Corporation, the brainchild of former Neuralink president Max Hodak, has officially entered a new frontier in human augmentation. The company recently announced the successful implantation of its vision-restoring device, PRIMA, into its first patient suffering from Stargardt disease—an inherited, currently incurable condition that leads to the gradual degradation of central vision.
Speaking on stage at TechCrunch Disrupt, Hodak framed the milestone not merely as a medical breakthrough, but as a fundamental shift in how humanity interacts with the central nervous system. By treating the retina as a legitimate, accessible extension of the brain, Science Corporation is setting the stage for a new generation of brain-computer interfaces (BCIs) that prioritize therapeutic efficacy and long-term health span over speculative consumer applications.
The Core Innovation: PRIMA and the Mechanics of Vision
At the heart of this announcement is the PRIMA system, a sophisticated retinal prosthesis that has already secured regulatory approval in Europe for treating geographic atrophy—the advanced stage of age-related macular degeneration. Stargardt disease, which affects approximately 150,000 people globally, presents a unique challenge: it causes the death of the retina’s light-sensing photoreceptors while often leaving the inner retinal layers, which transmit visual signals to the brain, intact.
The PRIMA implant acts as a bridge for these signals. During a one-hour surgical procedure, a tiny, 2mm-by-2mm chip is placed beneath the retina. Patients then wear specialized glasses equipped with cameras that capture the surrounding environment and project that visual data onto the implant. The chip converts this visual information into electrical impulses, essentially serving as a bionic photoreceptor layer.
"The retina is part of the central nervous system," Hodak explained during his keynote. "We consider cochlear implants, retinal prostheses, and motor prostheses as different types of BCIs. Vision, at its core, is just electrical activity traveling down the optic nerve. If you can facilitate the correct signaling to the brain, you can restore a sense of sight."
Chronology of the Clinical Journey
The path to this moment has been one of rigorous, measured progress. Since the company’s inception in 2021, Science Corporation has focused on validating its technology through controlled, high-impact medical applications.
- 2021: Max Hodak departs Neuralink to found Science Corporation with the mission of advancing neural engineering beyond traditional invasive brain-tissue probes.
- Late 2025: The company begins publicizing its broader vision for neural interfaces, distinguishing itself by focusing on devices that rest on the brain’s surface rather than penetrating delicate neural tissue.
- May 2026: The first patient with Stargardt disease is implanted with the PRIMA device at the Sydney Eye Hospital in Australia.
- July 2026: PRIMA receives official regulatory approval in Europe for broader clinical use.
- October 2026: Initial rehabilitation sessions demonstrate significant success. In the first session, the patient successfully identified a letter; by the second session, they were able to read an entire word.
This rapid progress in a clinical setting serves as a proof-of-concept for the company’s broader, long-term ambitions in neuro-engineering.
Supporting Data and Technical Challenges
While the results are promising, Hodak remains transparent about the current limitations of the technology. The current iteration of the PRIMA implant offers what he describes as a "straw-like" field of view.
"The device provides high-contrast, black-and-white, sharp vision, but it is currently a patch in the central field of view," Hodak noted. "The patient can see a few letters at a time, but it is not a full-color, wide-angle experience."
To evolve the technology, the engineering team at Science Corporation is focusing on three key metrics:
- Field of View Expansion: Developing larger implants that can conform to the natural curvature of the human eye.
- Electrode Miniaturization: Shrinking the electrode array to achieve pixel density that approaches natural visual acuity.
- Neural Integration: Improving the signal-to-noise ratio to ensure that the "artificial" visual input is interpreted as clearly as possible by the visual cortex.
The company is already iterating on a "next-generation" model, which is slated for human trials within the next year. Hodak projects that within five years, the system will achieve visual acuity levels that are nearly indistinguishable from native sight for patients currently living with blindness.
The Broader BCI Strategy: Beyond the Eye
Science Corporation’s strategy is distinct from its competitors in the BCI space, most notably Neuralink. While Neuralink’s primary methodology involves inserting "threads" directly into brain tissue, Science Corporation’s sensor technology is designed to rest on the surface of the brain, minimizing tissue trauma while still accessing critical neural data.
This approach is particularly promising for neurodegenerative diseases and post-stroke recovery. By identifying two distinct areas of the brain and facilitating communication between them, the company hopes to "add" new cortical functions—essentially helping the brain bypass damaged regions.
"We are currently working on a clinical indication involving a major neurodegenerative disease that most people have heard of," Hodak said, maintaining secrecy regarding the specific target. "We are also looking at stroke, where the goal is to bridge damaged circuits to restore lost functionality."
Implications: The Future of Health Span
Perhaps the most ambitious aspect of Science Corporation’s mission is its long-term view of human longevity. Hodak suggests that the integration of BCIs into the aging process is not a question of "if," but "when."
"We aren’t designing these for healthy 40-year-olds," Hodak clarified, acknowledging the ethical and technical hurdles of elective neuro-augmentation. "However, by the time people reach 60 or 70, the utility of a BCI becomes much more apparent. We are looking to extend not just our lifespan, but our health span."
The Philosophical Horizon
The ultimate goal of Science Corporation extends far beyond current medical applications. Hodak describes a long-term roadmap that seeks to decode the fundamental relationship between the brain and the mind. By building "engineered brains"—or at least the interfaces to support them—the company is positioning itself at the nexus of neuroscience and artificial intelligence.
As the company continues its work in Australia and expands its regulatory footprint, the implications for the future of medicine are profound. By solving the "vision problem" first, Science Corporation is building the trust, the data, and the hardware necessary to tackle the most complex mysteries of the human brain.
The success of the Stargardt patient is more than a win for the patient; it is a validation of a new philosophy in biotech. It suggests that by focusing on high-need clinical outcomes and prioritizing the longevity of the patient, the next revolution in computing won’t happen on a desk or a phone, but within the very architecture of our own minds.
Summary of Key Takeaways
- Technological Shift: Science Corporation is prioritizing surface-level neural interfaces that minimize brain-tissue damage.
- Clinical Success: The PRIMA implant has demonstrated immediate, actionable results in early rehabilitation for Stargardt disease patients.
- Roadmap: The company is moving from retinal restoration to deep-brain interfaces for stroke and neurodegeneration within the next half-decade.
- Longevity Focus: The firm views BCIs as a necessary tool for maintaining human health and function as the global population ages.
As Science Corporation continues its clinical trials, the global medical community will be watching closely to see if this "first word" read by a patient is indeed the beginning of a new chapter in human history.
Nana
